

1
2
3 **St. Luke's University Health Network**
4 **Informed Consent Document for Human Subjects Research**

5 **Department:** Neurosurgery

6
7 **Principal Investigator:** Steven Falowski, MD **Telephone:** 484-526-6000

8
9 **Co-Investigator(s):** Hugh Moulding, MD **Telephone:** 484-526-6000

10
11 **Medical Study Title:** NAPS (Non-awake versus Awake Placement of Spinal cord stimulators) Study
12 for the evaluation of awake and non-awake methods of SCS paddle lead placement

13
14 **Lay Study Title:** A Study to determine whether non-awake placement is comparable to awake
15 placement of spinal cord stimulators for achieving paresthesia coverage in chronic pain patients

16
17 **Sponsor:** St. Luke's University Health Network with Funding from St. Jude Medical

18
19
20 **What Is Informed Consent?**

21
22 You are being asked to take part in a medical research study. As required by federal regulations,
23 this research study has been reviewed and approved by an Institutional Review Board (IRB), a
24 committee that reviews, approves and monitors research involving humans. Before you can make
25 a decision about whether to participate, you should understand the possible risks and benefits
26 related to this study. This process of learning and thinking about a study before you make a
27 decision is known as *informed consent* and includes:

- 28
- 29 • Receiving detailed information about this research study;
 - 30 • Being asked to read, sign and date this consent form, once you understand the study and
31 have decided to participate. If you don't understand something about the study or if you
32 have questions, you should ask for an explanation before signing this form;
 - 33 • Being given a copy of the signed and dated consent form to keep for your own records.

34 You should understand that your relationship with the study doctor is different than your
35 relationship with your treating or personal doctor. The treating doctor treats a specific health
36 problem with the goal of improving a medical condition. A study doctor treats all subjects
37 according to a research plan to learn about the experimental drug, device or procedure being
38 studied and with the understanding that you may or may not benefit from being in the study. You
39 should ask questions of the study doctor and/or study team if you want to know more about this.

40
41
Subject Initials: ____
Date: ____

42 **What is the purpose of this study?**

43
44 You are being asked to participate in this study because you have had a successful spinal cord
45 stimulation (SCS) trial and are indicated for permanent implantation. SCS has been used for
46 many years and has proven to be effective in the treatment of chronic, intractable pain. Leads are
47 placed in the epidural space, which apply electrical stimulation to the spinal cord. Lead
48 placement has historically been done under awake conditions, using direct feedback from the
49 patient in order to define adequate paresthesia coverage. This could be stressful for the patient
50 and predisposes them to movement, which can lead to decreased patient satisfaction, equipment
51 migration, undesired stimulation effects, and treatment failure. Implantation under general
52 anesthesia (non-awake) is potentially more comfortable for the patient and may carry less risk for
53 revision.

54
55 The purpose of this study is to collect data necessary to demonstrate the safety and efficacy of
56 non-awake implantation of SCS paddle leads compared to the awake procedure. This study is
57 designed to evaluate whether non-awake placement reduces procedure time, complication rates,
58 and/or revision rates while offering comparable paresthesia coverage as the awake procedure.

59
60 This study will be carried out at the following institutions using the technique as indicated
61 (Awake versus Non-Awake). You will be assigned to the Non-Awake procedure here at St.
62 Luke's University Health Network.

- 63
- 64 • St. Luke's University Health Network (Non-Awake)
 - 65 • Thomas Jefferson University Hospital (Non-Awake)
 - 66 • Geisinger Medical Center (Awake)
 - 67 • Milton S. Hershey Medical Center (Awake)
- 68

69 **How many individuals will participate in the study and how long will the study last?**

70
71 Approximately 50 patients will participate nationally. We hope to enroll approximately 20
72 patients at St. Luke's University Health Network. Your involvement in the study will last about
73 24 weeks.

74
75 **What will I have to do during the study?**

76
77 If you are willing to participate in the study, you will sign the informed consent. You will then be
78 evaluated for eligibility, which will include a report of medical history, current medications, and
79 completion questionnaires (described in detail below).

80

Subject Initials: ____
Date: ____

81 **Questionnaires**

82 You will be given questionnaires to complete on your own. It is important that you understand
83 the meaning of all the words in the questionnaires, and ask any questions about the
84 questionnaires if further explanation is needed. Below is a listing of questionnaires you will be
85 asked to complete:

86

87 **Short-Form McGill Pain Questionnaire (SF-MPQ-2)**

88 The Short-Form McGill Pain Questionnaire version 2 (SF-MPQ-2) is a widely used scale used to
89 measure the major symptoms of both neuropathic and non-neuropathic pain. This questionnaire
90 consists of a set of 22 different pain descriptors. You will be instructed to indicate how
91 accurately the descriptor word describes your pain on a scale ranging from 0 ('None') to 10
92 ('Worst Possible'). The questionnaire takes approximately 5-10 minutes to complete.

93

94 **Pain Evaluation Form**

95 You will be provided with a questionnaire at follow-up visits to complete to evaluate your pain
96 relief from the device and rate your current, average, worst, and least pain.

97

98 **EuroQol (EQ-5D) generic health index questionnaire**

99 EQ-5D is a standardized instrument for measuring health outcome using a standard layout for the
100 five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) of
101 your health state.

102

103 **Pain Location Form**

104 The Pain Location Form includes a map of the body that is labeled with different numbered
105 regions. You will be instructed to shade in or place an X in the area where you are feeling pain.

106

107 **Paresthesia Coverage Form**

108 The Paresthesia Coverage Form includes a map of the body that is labeled with different
109 numbered regions. You will be instructed to shade in or place an X the area where you are
110 feeling stimulation/paresthesia. You will also indicate which area(s) of pain relief have had the
111 greatest improvement over your daily activities.

112

113 **SCS Permanent System Implantation**

114 You will be prepped for surgical paddle lead placement according to usual practice, including
115 anesthesia and customary intraoperative monitoring.

116

117 **Lead Placement for Awake Arm**

118 Upon approximate lead positioning, you will be brought to a conscious sedated state while
119 maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead will be
120 accomplished with an external pulse generator. You will be asked about your pain to determine
121 paresthesia coverage of painful regions. Upon satisfactory coverage, the IPG will be implanted

Subject Initials: ____

Date: ____

122 per usual practice.

123

124 Lead Placement for Non-awake Arm

125 You will be maintained under general anesthesia for the full duration of the implant. Upon
126 approximate lead positioning, EMG monitoring for SCS coverage of pain areas will be done.
127 Stimulation is delivered through the lead by an external pulse generator. Upon satisfactory
128 coverage, the IPG will be implanted per usual practice.

129

130 **Postoperative Management and Instruction**

131 The physician will provide normal standard of care after implantation of the system, including
132 standard post-operative monitoring. Instructions for wound care and monitoring will be provided
133 and you will be sent home for a 2-3 week recovery period to let any swelling and/or post-
134 operative pain subside prior to activation of SCS system, unless otherwise determined by the
135 installing investigator.

136

137 **Device Activation**

138 The permanent system device activation visit will occur approximately 2-3 weeks after
139 permanent system implantation. At this visit, you will have your device programmed per usual
140 practice. A map of paresthesia coverage will be collected, along with final programmed
141 parameters, lead impedance, and device data. Any changes in medications will be noted, and
142 you will be asked to complete the Patient Global Impression Form to assess your satisfaction
143 with the permanent implant procedure.

144

145 **Follow-up Visits**

146 You will report to the office at the specified intervals below. Under the guidance of the
147 Investigative team at each visit, SJM field representatives may assist with programming of your
148 device as needed during the course of the study.

149

150 • 6 Week and 24 Month Visits

151 You will be monitored for the safety and efficacy of the therapy, and the following will
152 be collected/completed:

- 153 ○ A map of paresthesia coverage along with programming parameters, lead
154 impedance, and device data
- 155 ○ Changes in medications
- 156 ○ Pain metrics via self-reported pain relief, NRS, and SF-MPQ
- 157 ○ Quality of Life (EQ-5D)

158

159 • Unscheduled Visit

160 An Unscheduled Visit form will be used if you make an unscheduled office visit. The
161 Healthcare Utilization (HCOR) form will be completed for all unscheduled visits.

162

Subject Initials: ____
Date: ____

163 **What are the risks or discomforts involved?**

164
165 There are no additional risks from the standard of care, and possible loss of confidentiality. However,
166 measures will be taken to prevent loss of confidentiality as described below.

167
168 You should call the study doctor as soon as possible at 484-526-6000 if, during the course of this
169 study, you develop any of side effects or symptoms. The study doctor has told you that if your
170 condition worsens, if side effects become very severe, or if it turns out that being in this study is
171 not in your best interest, you will be taken out of the study.

172
173 **What are the risks to fetuses, infants and pregnant women?**

174
175 Pregnant women will not be included this study because the effects of SCS to the mother,
176 embryo, and fetus are unknown. To be in this study you and your partner must practice adequate
177 birth control measures. The study doctor will discuss acceptable methods of birth control with
178 you. If you are a woman of childbearing potential, you will have a pregnancy test before making
179 a decision about being in this study. This requires either a urine test or that blood be drawn from
180 a vein in your arm (1-2 tsp.) prior to the start of the study and according to study guidelines. The
181 results of this pregnancy test will be made available to you prior to the start of the study.

182
183 If you become pregnant during the course of this study, you should notify the study doctor as
184 soon as possible.

185
186 **Are there alternatives to being in the study?**

187
188 You do not have to participate in this study.

189
190 **HIPAA Authorization: How will privacy and confidentiality (identity) be protected?**

191
192 Federal regulations require that certain information about individuals be kept confidential. This
193 information is called "protected health information" (PHI). PHI includes information that
194 identifies you personally such as name, address and social security number, or any medical or
195 mental health record, or test result, that may have this sort of information on it. The laws state
196 that you may see and review your St. Luke's University Health Network medical records at any
197 time. However, in a research study, you may not see the study results or other data about the
198 study until after the research is completed unless the study doctor decides otherwise.

199
200 If you join this study, the following individuals or entities may have access to your PHI and by
201 law must protect it. These include investigators listed on this consent form and other personnel
202 of St. Luke's University Health Network involved in this specific study, including the

Subject Initials: ____
Date: ____

203 Institutional Review Board (IRB), and your health insurance company (if necessary for billing
204 for standard medical care). It may also be provided to other people or groups as follows:

- 205
- 206 • Researchers at Thomas Jefferson University Hospital, Geisinger Medical Center, and
207 Milton S. Hershey Medical Center

208

209 Your PHI may also be shared with the following entities that, while not obligated by law to
210 protect PHI, will protect it to the best of their ability:

- 211 • St. Jude Medical which is providing funds to St. Luke's University Health Network to
212 conduct this research
- 213 • The Food and Drug Administration (FDA)
- 214 • With any person or agency required by law.

215

216 The following information will be provided to the study sponsor and other entities noted above:

217

218 **Study data for analysis:** Questionnaires, Medical History and medications, surgery and device
219 information

220 **Demographic data:** gender, age, height, weight, ethnicity, marital status

221

222 If you develop an illness or injury during the course of your participation in this study, other PHI
223 about treating and following the condition may be generated and disclosed as it relates to this
224 study. Your PHI may be used/ disclosed indefinitely.

225

226 You may quit the study and revoke permission to use and share your PHI at any time by
227 contacting the principal investigator, in writing, at:

228

229 **Steven Falowski, MD**
230 **701 Ostrum Street, Suite 302**
231 **Bethlehem, PA 18015**

232

233 If you quit the study further collection of PHI will be stopped, but PHI that has already been
234 collected may still be used.

235

236 The results of clinical tests and procedures performed as part of this research may be included in
237 your medical records. The information from this study may be published in scientific journals or
238 presented at scientific meetings but you will not be personally identified in these publications and
239 presentations.

240

241 After your information is shared with others, like the sponsor, it may no longer be protected by
242 the Privacy Rule. The people who receive this information could use it in ways not discussed in
243 this form and could disclose it to others. The sponsor will use and disclose information about you

Subject Initials: ____
Date: ____

244 only for research or regulatory purposes or to prepare research publications. In addition to using
245 it for this study, the sponsor may reanalyze the study data at a later date or combine your
246 information with information from other studies for research purposes not directly related to this
247 study. When using the information in these ways, the sponsor may share it with other
248 researchers, its business partners, or companies hired to provide research-related services.
249 However, your name will never appear in any sponsor forms, reports, databases, or publications,
250 or in any future disclosures by the sponsor.

251
252 A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required
253 by U.S. Law. This Web site will not include information that can identify you. At most, this Web
254 site will include a summary of the results. You can search this Web site at any time.
255

256 **What if I am injured as a result of being in this study?**

257
258 In the event that you experience a research-related injury, necessary and available medical care
259 (including hospitalization) will be provided. A research-related injury is a physical injury or
260 illness resulting to you that is directly caused by any procedure or treatment used in this study
261 that is different from the treatment you would receive if you were not participating in a research
262 study. If you are physically injured due to any procedure properly given under the plan for this
263 study, medical expenses for treating the injury will be billed to your insurance carrier. You
264 should be aware that some costs may not be covered by insurance. There is no plan to provide
265 compensation for loss of wages, lost time from work, personal discomfort, or for injuries or
266 problems related to your underlying medical condition(s).

267
268 If you receive a bill related to a research-related injury that seems wrong, please discuss it with
269 the study doctor or research coordinator.

270 271 **Will I benefit from being in this study?**

272
273 You may not benefit from being in this research, but we hope that what we learn may be helpful
274 to future patients or society in general.

275 276 **Will I be paid for being in this study?**

277
278 You will not receive payment for your participation in this study.

279
280 In addition, you will not be paid if inventions and/or patents are developed from the study
281 results.

282

Subject Initials: ____
Date: ____

283 **Will I be told about any new findings?**

284
285 Anything learned during the study, beneficial or not, that may affect your health or your
286 willingness to continue in the study, will be told to you and explained.

287
288 **Disclosure of Financial Interest**

289
290 The funding sponsor of this clinical study, St. Jude Medical, is paying St. Luke's University
291 Health Network to conduct this study.

292
293 **Are there costs related to being in this study?**

294
295 ***Research Procedures***

296
297 There are no investigational devices being used in this study, and all services will be billed to
298 your insurance.

299
300 ***Standard Testing Procedures***

301
302 Procedures, tests and doctor's charges resulting from being in the study that are considered
303 standard of care will be billed to your health insurance carrier. These are charges that you would
304 have whether or not you were participating in a research study. It is possible that your insurance
305 company may deny payment. If that happens you may be responsible for some or all of these
306 charges. All services are standard of care in this study.

307
308 If you receive a bill that you think is wrong, please discuss it with the study doctor or research
309 coordinator.

310
311 **Can I be removed from the study or quit the study?**

312
313 Your decision to participate in this research study is entirely voluntary. You have been told what
314 being in this study will involve, including the possible risks and benefits.

315
316 Your participation in this research project may be terminated by the study doctor without your
317 consent for any reason that he/she feels is appropriate.

318
319 You may refuse to participate in this investigation or withdraw consent and quit this study
320 without penalty and without affecting your ability to receive medical care at St. Luke's
321 University Health Network.

322

Subject Initials: ____
Date: ____

323 If you withdraw from this study, you may continue treatment with your St. Luke's University
324 Health Network doctor, or you may seek treatment from another doctor of your choice.

325
326 Should you decide to withdraw from the study, please be sure to inform the study doctor.
327 Additional tests or procedures may be needed to ensure your safety. The study doctor will
328 explain why these tests or procedures are necessary.

329
330
331 **CONTACT INFORMATION**
332

Telephone number for questions about your rights as a research participant	St. Luke's University Health Network Institutional Review Board	484-526-4669
For questions, concerns or complaints about the research, or if you suspect a research-related injury	The Principal Investigator, Dr. Steven Falowski or any co-investigator listed at the beginning of this form	484-526-6000

333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354

Subject Initials: ____
Date: ____

